Literature DB >> 8514061

An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.

D S Levine1, R C Haggitt, P L Blount, P S Rabinovitch, V W Rusch, B J Reid.   

Abstract

BACKGROUND: Surveying vs. performing resection in patients with high-grade dysplasia in Barrett's esophagus is debated because of concern about the accuracy of endoscopic biopsy diagnosis. The aim of this study was to investigate the accuracy of an endoscopic biopsy protocol in patients with neoplastic abnormalities in Barrett's epithelium without obvious esophageal cancer.
METHODS: Preoperative and postoperative diagnoses in 28 patients who underwent surgery for high-grade dysplasia or early adenocarcinoma in Barrett's esophagus and compared them with 22 other patients with high-grade dysplasia who were maintained under prospective endoscopic surveillance. All 50 patients lacked gross lesions to suggest esophageal cancer. The endoscopic protocol involved rigorous, systematic acquisition of multiple, large biopsy samples.
RESULTS: Overall, 64% of patients had minimal but distinct endoscopic abnormalities that were targeted for biopsies. High-grade dysplasia alone (7 patients) was differentiated from early adenocarcinoma (19 patients). Two patients with preoperative diagnoses of intramucosal adenocarcinoma had high-grade dysplasia in their resection specimens.
CONCLUSIONS: This endoscopic protocol accurately detects and differentiates high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Patients with high-grade dysplasia alone in Barrett's esophagus detected by such a protocol do not necessarily require surgical resection to rule out an undiagnosed adenocarcinoma; electing for surgery should be based on other clinical considerations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514061     DOI: 10.1016/0016-5085(93)90008-z

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  135 in total

1.  ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting.

Authors:  N B Ibrahim
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

Review 2.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 3.  Pathology of Barrett's esophagus.

Authors:  R C Haggitt
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 4.  High-grade dysplasia in Barrett's esophagus: surveillance or operation?

Authors:  C A Pellegrini; D Pohl
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

5.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

6.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

7.  [Barrett esophagus: epidemiology, incidence of carcinoma, need for screening].

Authors:  R Arnold; M Wied
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

8.  Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works?

Authors:  D Alderson
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

9.  S, m, l, xl.

Authors:  T Wang; G Triadafilopoulos
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

10.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.